The negative regulation of angiogenesis may provide a promising therapeutic target for a number of lifestyle-related diseases, as the switch to an angiogenic phenotype in many tissues represents a critical step during the progression of such disorders. Cartilage is avascular and shows resistance to vascular invasion from the surrounding well-vascularized mesenchyme. Using guanidine extracts of fetal bovine cartilage, we have identified and purified chondromodulin-I (ChM-I) as an angiogenesis inhibitor. The cDNA sequence of this factor has revealed that the ChM-I precursor protein is a type II transmembrane glycoprotein (334 amino acids) and that mature ChM-I is encoded in the C-terminal region of the precursor. After cleavage of the ChM-I precursor at its processing site, mature ChM-I (120 amino acids) is secreted from chondrocytes into the extracellular matrix. Following on from the identification of ChM-I as an angiogenesis inhibitor in cartilage, we have also cloned both mouse and human tenomodulin (TeM), which share significant homology with ChM-I at their C-termini. Moreover, exogenous expression experiments in COS cells suggests that TeM is a type II transmembrane glycoprotein (317 amino acids). When overexpressed in HUVECs, the C-terminal domain (116 amino acids) of the TeM protein shows both anti-angiogenic and anti-tumorigenic activities at equivalent levels to mature ChM-I. In our present review, we discuss the structure, biological activities and localization of these anti-angiogenic molecules.
INTRODUCTION
The vasculature is the first organ to appear during development in vertebrates as this closed circulatory system is crucial for providing the oxygen and nutrients necessary for growth. The growth and metastasis of solid tumors can often be dependent on their extraordinary levels of neovascularization that are induced by the action of tumor angiogenic factors. Following the pioneering hypothesis of Folkman [1] that anti-angiogenic therapy can be an effective anti-tumor strategy, a variety of attempts have been made to identify agents that inhibit tumor angiogenesis. Intensive studies for more than a decade have now established that vascular endothelial growth factors (VEGFs) play a central role in the regulation of both physiological and pathological angiogenesis, in addition to fibroblast growth factors (FGFs), hepatocyte growth factor (HGF) and the angiopoietins [2] . Much attention has been paid also to recent clinical trials of anti-VEGF antibodies as a viable tumor therapy [3] .
In contrast to other tissue types, cartilage has been shown to be avascular and to be resistant to neovascularization and tumor invasion [4, 5] . Despite this characteristic, however, cartilage is still a rich source of angiogenic molecules such as FGF [6, 7] and transforming growth factor-(TGF-) [8] , indicating that it is potentially angiogenic. During the replacement of cartilage by capillary invasion, and subsequent bone formation via endochondral ossification, hypertrophic cartilage expresses VEGF [9] . For the maintenance of an anti-angiogenic phenotype, cartilage thus requires the presence of anti-angiogenic molecules to counterbalance the effects of factors such as VEGF. We have identified chondromodulin (ChM-I) and tenomodulin (TeM) as tissue-specific macromolecules that are capable of inhibiting angiogenesis. This review focuses on the pathophysiological role of these molecules from the standpoint of both their structure and specific pattern of expression.
ANTI-ANGIOGENIC RESISTANCE IN THE MESENCHY-ME
Epithelial cell layers require tight cell-cell junctions to perform their functions and thus any associated capillary ingrowth would result in a fundamental disruption to this. Hence, under normal conditions, capillaries never extend to the epithelial cell layer beyond the underlying basement membrane that segregates the epithelium from the mesenchyme (Fig. (1) ). The basement membrane is an amorphous dense sheet-like structure that functions as an "anti-angiogenic barrier" in the epithelium. Major components of the basement membrane include type IV collagen, laminin and the heparan-sulfate proteoglycans, as well as minor components such as osteopontin, type XV collagen and XVIII collagen. Thrombospondin-1 (TSP-1), a large extracellular glycoprotein, is a well-characterized basement membrane component that inhibits angiogenesis in vitro and in vivo [10] . Endothelial cell sheets of capillaries are also surrounded by the vascular basement membrane that contributes to stabilization of blood vessels. Over the past decade, a number of cryptic anti-angiogenic domains have been identified in these extracellular matrix (ECM) components [11] . Induction of sprouting angiogenesis triggers proteolytic degradation of the vascular basement membrane and liberates a variety of cryptic angiogenesis inhibitors in circulation such as endostatin (derived from type XVIII collagen).
The mesenchyme that supports the epithelium is both wellvascularized and pro-angiogenic, and most organ stroma and connective tissues readily allow the ingrowth of vessels upon stimulation by inflammation or hypoxia. Therefore, it seems reasonable to assume that there is a distinct molecular basis for shielding the hypovascular domains of the mesenchyme from this invading vasculature (Fig. (1) ). Early studies have implicated the presence of specific angiogenesis inhibitors in this process. These factors are synthesized by chondrocytes and tightly bound within the ECM of cartilage, and only a dissociative extraction method could release angiogenesis inhibitory activity into solution and suppress solid tumor growth [12, 13] . Thus, bovine and shark cartilage has been established as a source of angiogenesis inhibitors for purification [14] . The initial biochemical characterization of the inhibitors suggested that the anti-angiogenic activity of the extracts was related to the inhibition of protease activity. This observation led to the isolation by the Folkman group of both a cartilagederived collagenase inhibitor [15] , and a chondrocyte-derived inhibitor (ChDI) of angiogenesis from the conditioned medium of bovine scapular chondrocytes in culture [16] . Tissue inhibitors of metalloproteinase-2 (TIMP-2) were also identified as suppressors of angiogenesis from the conditioned medium of cultured human chondrosarcoma cells [17] . In addition, troponin I was purified from cartilage to apparent homogeneity and shown to be a potent and specific inhibitor of angiogenesis, both in vivo and in vitro [18] . However, the physiological relevance of troponin I in the control of angiogenesis is not yet clear.
Previously, we prepared extracts of fetal bovine epiphyseal cartilage with 1 M guanidinium chloride and confirmed that the size-fractionated cartilage extracts (10-50 kDa fraction) inhibited the growth of cultured bovine aortic endothelial cells in a dosedependent manner [19] (Fig. (2) ). Tumor angiogenesis was also successfully inhibited in our experiments, in agreement with the previous seminal observations [12, 13] . Furthermore, as shown in Fig. (3) , this fraction also inhibited the ingrowth of capillaries to the cartilage during ectopic bone formation that had been induced by demineralized bone matrix (DBM) [20] . When implanted into the fascia of nude mice, DBM pellets readily induced cartilaginous tissue that was then replaced by bone within three weeks, in association with capillary ingrowth into the pellets. However, when these pellets had been mixed with the 10-50 kDa fraction of cartilage extracts, the cartilage persisted without capillary ingrowth and bone formation failed to occur [20] . Hence, endogenous angiogenesis inhibitors may participate in the interaction between tissues and the vasculature during their formation and remodeling.
MOLECULAR STRUCTURE OF CHONDROMODULIN-I AND TENOMODULIN
Cartilage contains growth-stimulating activity to promote its own growth and maturation. Following the purification and subsequent identification of cartilage-derived growth factor as basic FGF (FGF-2) [6, 21] , we purified a novel 25 kDa glycoprotein from the guanidine extracts of fetal bovine epiphyseal cartilage, termed Fig. (2) . The effects upon DNA synthesis following the exposure of cultured aortic endothelial cells to fractionated cartilage extracts [19] . Thymidine incorporation was measured in bovine carotid artery endothelial cells in subconfluent cultures in the presence of 10% FBS (fetal bovine serum). Each of the data points represents the mean ± standard deviation of triplicate assays. . (3) . The effects of cartilage extracts on ectopic bone formation [20] . Pellets of bovine demineralized bone matrix (DBM) were implanted into the fascia of the back muscles in nude mice. The implants were recovered three weeks after implantation and sections were stained with hematoxylin-eosin. (A), trabecular bone (tb) and bone marrow (bm) development in the pellet (15 mg). (B), cartilaginous tissue (ca) with little evidence of vascular invasion developed in the DBM pellet, which had been previously mixed with fractionated 10-50kDa bovine cartilage-extracts (CE, 2 mg). The inset shows a large number of chondrocytes undergoing hypertrophy. Bars, 100 m in (A) and (B).
chondromodulin-I (ChM-I) [22] . ChM-I was found to stimulate DNA synthesis in cultured growth-plate chondrocytes in the presence of FGF-2. As ChM-I also stimulates proteoglycan synthesis in chondrocytes, it was observed to markedly enhance the colony formation of these cells in soft agarose in the presence of FGF-2 [23] . Moreover, the potency of ChM-I as a chondrocytecolony stimulating factor was equivalent to TGF-. Thus, the presence of ChM-I in the cartilage ECM may promote both the growth and maturation of cartilage. In a separate experiment, we purified the growth inhibitory activity from the cartilage extracts by monitoring the inhibition of DNA synthesis of aortic endothelial cells. The fraction containing this inhibitory activity bound to a heparin affinity column and was eluted by 0.5-1.2 M NaCl (Fig.  (2) ). N-terminal sequencing of the purified inhibitor revealed that it was identical to ChM-I [19] . Bovine ChM-I (121 amino acids) was found to be glycosylated at residues Asn 29 , Thr 9 and Thr 22 within the N-terminal hydrophilic domain [22, 24] . The C-terminal two thirds of the protein contains a hydrophobic region and eight Cys residues, which form four disulfide bonds [24] .
Molecular cloning of ChM-I cDNA revealed that the mature molecule is encoded within the C-terminal region of the larger type II transmembrane precursor (pre-ChM-I) ( Fig. (4) and Fig. (5) ). The mature ChM-I sequence is preceded by a processing signal (RXXR at position 211-214 in pre-ChM-I) for furin-like endoproteases, suggesting that it is secreted out of cells following glycosylation and cleavage from the membrane-anchored precursor. The putative residual transmembrane precursor was designated as an unidentified chondrosurfactant protein, because a portion of the ChM-I precursor shares a significant degree of homology with pulmonary surfactant apoprotein C (SP-C) [22] . Furthermore, when a fulllength pre-ChM-I cDNA was transfected into either CHO or COS-7 cells, the correct N-terminal amino acid sequence could be obtained from the recombinant ChM-I protein that we purified from the conditioned medium of these cultures [19, 25] . Western blotting subsequently suggested that there were no significant levels of unprocessed precursor protein in the cell layers. Moreover, no proteolytic cleavage occurred when the predicted cleavage site was mutated from RERR to RERQ, or when the pre-ChM-I cDNA was expressed in furin-deficient CHO cells [26] .
Screening of a human cosmid library revealed that the human pre-ChM-I gene comprises seven exons with a TATA-less type promoter that span a region of over 40 kb on chromosome 13 (13q14.3) [27] . In addition, the mouse and zebrafish ChM-I loci are syntenic to this region [28] . The last two exons encode the mature secreted form of ChM-I. Exon 6 corresponds to the RERR processing signal and the N-terminal hydrophilic domain that contains glycosylation sites. Exon 7 corresponds to the C-terminal Cys-rich domain (71 amino acid residues), which is essential for the growth-modulating actions of ChM-I and which is highly conserved across species at the amino acid level. There is only one amino acid difference between the mouse and human sequences of this domain (Val 320 to Ile 320 ), as shown in Fig. (4) .
In 2001, four groups, including our laboratory, independently reported the identification of a novel type II transmembrane protein of 317 amino acids bearing a Cys-rich domain at the C-terminus that is highly homologous to ChM-I [29] [30] [31] [32] (Fig. (4) ). We termed this factor tenomodulin (TeM), after tenocytes, as it is predominantly expressed in tendons [29, 30, 33] . The human TeM gene was mapped to chromosome X (Xq22.1) and contains seven exons, the last of which encodes the conserved Cys-rich domain which is 59% identical to ChM-I. Each of the eight Cys residues in this domain are also conserved and are identically spaced, with one exception (Fig. (4) ). When we transfected cDNA containing the entire coding region of TeM tagged with FLAG in COS7 cells or human umbilical vein endothelial cells (HUVECs), the expressed recombinat TeM protein was detected as a double band with an apparent molecular mass of 40 and 45 kDa [31, 33, 34] . This is in good agreement with the predicted full-length TeM protein consisting of 317 amino acids with differential glycosylation. We detected naturally occurring mouse TeM by immunoblotting as a double band with a molecular mass of 40 and 45 kDa in extracts of the eye or the skeletal muscle containing epimysium [33, 34] . Cell surface biotinylation and cell surface labeling experiments revealed that the TeM protein is expressed as a type II transmembrane protein with a short cytoplasmic tail and with the C-terminus expressed on the exterior cell surface. Dechesne and co-workers also confirmed that TeM protein was detected as a cell surface protein when mouse TeM with FLAG tag was overexpressed in mouse C2C12 myoblasts [35] . They detected no evidence for short cleavage product of TeM protein. However, Brandau and co-workers reported that a 16 kDa immunoreactive band corresponding to the mouse C-terminal Cysrich domain was detected in urea extracts of tail tendons from wild type mice, which was not observed in TeM null mice [36] . This short form might be generated after cleavage at the potential processing site (RXXR) at positions 233-236 ( Fig. (4) ), although we could not detect the cleaved form in the conditioned medium of COS7 cells or HUVECs expressing the entire coding of TeM. Alternatively, the extracellular domain of TeM are cleaved and released from cells in a soluble form by ectodomain shedding under certain conditions. Further studies have to be done to clarify how TeM protein is generated and processed during development of dense connective tissues.
In 2002, Valencia and co-workers reported the identification of the BRICHOS domain of approximately 100 amino acids in several previously unrelated proteins that includes BRI (for British dementia), ChM-I and SP-C (for pulmonary surfactant apoprotein C) [37] . The BRICHOS domain contains a pair of conserved Cys residues that are likely to form a disulfide bond (Fig. (5) ), as has been proposed for SP-C. Among the BRICHOS domain protein family members, the sequence conservation is predominantly located around these two Cys residues and mutation in one or both in the SP-C protein results in misfolding of the propeptide and mistargeting of the unprocessed species [38] . This suggests that there is a role for the BRICHOS domain in the complex posttranslational processing and targeting of mature proteins. However, the functional role of this domain in pre-ChM-I remains unclear since it was possible to produce the bioactive mature form of hChM-I by the direct expression of the cDNA fragment corresponding to the mature ChM-I portion (E 215 -V 334 of pre-ChM-I). The BRI family of genes comprises at least three members (BRI 1-3 ) which are type II transmembrane proteins, each of which contains a furin cleavage site near the C-terminus. However, unlike ChM-I and TeM, no Cys-rich domain is positioned after the furin cleavage site. Processing by furin results in secretion of a peptide of 24 amino acids, for which the physiological function is not known. However, proteolytic cleavage of the mutant BRI 2 gene results in secretion of a hydrophobic 34 amino acid product that accumulates in amyloid deposits in familial British dementia [39, 40] . It is also intriguing to note that the BRI 1 and BR 2 loci have been mapped on chromosomal regions Xq21.1 and chromosome 13q14.2, respectively, each of which is very close to those of TeM and ChM-I.
ANTI-ANGIOGENIC ACTIVITY OF CHM-I IN VITRO
In contrast to vasculogenesis, which relies on progenitor cell differentiation during organogenic development, angiogenesis is the process by which new capillaries are formed by sprouting from preexisting vessels (Fig. (1) ). During sprouting, vascular endothelial cells leave the vessel wall and migrate to invade the surrounding tissue. The proliferation and tube morphogenesis of endothelial cells follows and once tube formation has occurred, these cells secrete a basement membrane that stabilizes the neovessels by providing signals for the inhibition of proliferation and for subsequent maturation [41] . Purified ChM-I inhibits proliferation and DNA synthesis in human umbilical vein endothelial cells (HUVECs) in culture in a dose-dependent manner (IC 50 , 10-20 nM), as well as bovine aortic endothelial cells (Fig. (2) ) [19, 42] . Tube morphogenesis in human retinal vascular endothelial cells that had been induced by VEGF is also inhibited in a dose dependent manner [43] . Angiogenesis in chick chorioallantoic membrane (CAM) is also clearly inhibited by ChM-I [25] . Furthermore, upon reduction by dithiothreitol, ChM-I is rendered biologically inactive, suggesting that disulfide bonds are essential for its anti-angiogenic activity.
Dechesne and coworkers have previously identified TeM as a down-regulated gene in a muscle atrophy model [35] . A low level of TeM transcripts was detectable in myoblasts. Using C2C12 myoblasts that overexpress membrane-tethered TeM protein on their cell surfaces, the authors examined the interactions with H5V mouse cardiac vascular endothelial cells and suggested that TeM provides a favorable cell surface for endothelial invasion. We assessed the anti-angiogenic activity of TeM in our laboratory by the forced expression of the C-terminal 116 amino acids of human TeM protein (hTeM C-domain, E 202 -V 317 ) as a secreted factor in COS-7 cells. For comparison, the corresponding mature human ChM-I sequence (E 215 -V 334 of pre-ChM-I) was similarly expressed. When treated with conditioned medium containing expressed hChM-I, the HUVECs clearly failed to undergo tube morphogenesis on Matrigel. Expression of the hTeM C-domain resulted in the inhibition of tube formation to the same extent [34] . Conditioned medium from cells transfected with the entire extracellular domain of hTeM (H 52 -V 317 ) also inhibited this process, but conditioned medium from cells expressing other regions of hTeM, such as H 52 -E 201 and H 52 -E 254 , did not show these inhibitory effects. To further test the anti-angiogenic nature of the hTeM Cdomain, we attempted its forced expression in capillary endothelial cells as a secreted protein using an adenoviral system [33, 34] . Transduction of virus expressing the hTeM C-domain resulted in a significant impairment of the growth of human retinal vascular endothelial cells (HRECs) and suppression of tube formation in HUVECs (Fig. (7) ). Furthermore, in a modified Boyden chamber assay, the migration of HUVECs in response to VEGF was also significantly inhibited. Thus, we concluded from these data that the C-terminal domain of TeM initiates an anti-angiogenic response in cultured vascular endothelial cells in a manner similar to ChM-I.
Matrix metalloproteinases (MMPs) are known as important factors in neovascularization and vascular invasion since the initial stages of sprouting involve the proteolytic degradation of capillary basement membrane by MMPs, and other proteases. In mice lacking MMP9, vascular invasion and subsequent ossification were found to be delayed during endochondral bone formation, causing progressive lengthening of the growth plate [44] . However, this delay in ossification appeared to be secondary to a diminished vascular invasion into cartilage as MMP9-deficient hypertrophic cartilage fails to release normal levels of pro-angiogenic activity [45] . These results suggest that MMPs play a regulatory role in angiogenic switching of the cartilage phenotype during endochondral bone formation. Contrary to our expectations, however, no overt abnormalities in the vascular invasion of bone rudiments could be detected in mice following the targeted disruption of the TIMP genes, even though TIMP2 and TIMP3 are expressed in the developing cartilaginous rudiments [46] . MMP2 null mice do show reduced angiogenesis and tumor progression in vivo [47] . By virtue of their ability to inhibit MMP activity, the TIMP family members have been described as inhibitors of angiogenesis. MMP inhibitors are also potent inhibitors of angiogenesis and tumor growth in general. However, there is no current evidence to show that either ChM-I or TeM directly inhibits the enzymatic actions of the MMPs. In addition, no high-affinity binding sites have yet been identified in vascular endothelial cells for either ChM-I or TeM. Recently, TIMP2 and TIMP3 were shown to inhibit angiogenesis on the basis of a pathway that is unrelated to the inhibition of MMP activity [48, 49] .
TISSUE-SPECIFIC EXPRESSION AND GENE REGULA-TION OF CHM-I
Analysis of zebrafish development by in situ hybridization and RT-PCR has revealed that ChM-I is readily detectable in eggs as a maternally derived transcript. Following on from the cartilage marker Col2a1 transcripts that are detected at the 3 somite stage, zygotic ChM-I expression is first observed in the notochord at the 10 somite stage [28] . Interestingly, the transcripts for the endothelial marker Flk-1 also begin to be detectable at this same stage. At later stages of development, ChM-I is expressed in the areas surrounding the developing ears, in the craniofacial cartilage and in the mesenchymal condensation of the pectoral fins. The expression domain of ChM-I was also found to be narrower than the Col2a1 cartilage marker in the mesoderm and mesenchymal tissues. During the development of chicken embryos, ChM-I transcripts are expressed in the notochord, the floor and the roof plate of the neural tube, and in cartilage precursor tissues such as the sclerotomes of the somites, the developing limbs, the pharyngeal arches, the otic vesicle and the sclera [50, 51] . Moreover, ChM-I continues to be expressed as differentiated cartilage forms. Among the noncartilaginous domains of vertebrate embryos, a high level of ChM-I expression can also be detected in the developing heart, but rapidly diminishes as organogenic development proceeds in this organ.
Avian and mammalian ocular tissues are other important sites of ChM-I expression [43, 50, 52] . The vasculature is highly restricted in the eye, despite the presence of angiogenic molecules such as FGF-2 and VEGF. For the maintenance of transparency, blood vessels are completely excluded from the vitreous humor, cornea, sclera, lens, retinal pigment epithelium, outer retina, and the aqueous humor that fills the anterior chamber. Previously, we identified the localized expression of ChM-I in the cornea, ganglion cells, inner nuclear layer cells, the retinal pigment epithelium of the retina and non-pigment epithelium of the ciliary body [43, 53] . ChM-I protein can also be detected in the vitreous body or aqueous humor by immunostaining and western blotting, suggesting that ChM-I is synthesized and released from these cells into the vitreous body or aqueous humor as a mature glycosylated 25 kDa product. TeM transcripts are predominantly expressed in tendons, ligaments, and the epimysium of skeletal muscles [29, 30, 33] . TeM gene expression has also been confirmed in the ocular compartments, which include the sclerocornea, the lens fiber cells, the ganglion cell layer, the inner neural retina, the retinal pigment epithelium and the tendon of the extra-ocular muscle [33] . Overlapping or neighboring expression of these related angiogenesis inhibitors thus covers the avascular compartments of the eye, suggesting a role for these factors in the prevention of neovascularization in eye.
Undoubtedly, the rib and growth plate cartilage is the most prominent site of ChM-I expression in the mammalian body [19, 20] . As shown by immunofluorescent staining (Fig. (8A) ), mature ChM-I protein is clearly localized in cartilage core of ribs and is also present as a specific component of cartilage ECM. Taking its hydrophic nature into consideration [25] , it is now speculated that glycosylated mature ChM-I accumulates in cartilage ECM in a tightly bound association with an as yet unidentified matrix component. No unprocessed ChM-I precursor has been detected in the cytoplasm of chondrocytes, which is consistent with the active utilization of the predicted furin cleavage site [25, 26] . As shown in Fig. (8B) , the mammalian vasculature is segregated from cartilage by perichondrium. During development, ChM-I transcripts are induced during chondrogenesis [20] and are maintained at high levels in the anti-angiogenic avascular zone of the cartilaginous bone rudiments, which includes the resting, proliferating and early hypertrophic zone of cartilage. However, this expression was found to be completely abolished in the lower hypertrophic and calcified zones of cartilage, which allow vascular invasion in order to initiate endochondral bone formation (Fig. (8C) ). Fetal and adult articular cartilage also express ChM-I transcripts and contain mature ChM-I protein in the ECM. However, the levels of ChM-I mRNA are markedly lower in articular cartilage than in epiphyseal growth plate cartilage [53, 54] , and this is particularly evident in the superficial zone (Fig. (8D) ). Moreover, ChM-I expression rapidly declines with age at 8 weeks after birth in rats, but is still maintained in epiphyseal cartilage [53] .
In vitro studies support the contention that the expression of ChM-I occurs in a manner that is dependent upon chondrogenic differentiation. De-differentiation of chondrocytes by retinoic acid treatment abolishes the expression of ChM-I mRNA [50, 54] . Upon induction of chondrogenic differentiation, the mouse chondrogenic cell line ATDC5 begins to express ChM-I transcripts, whereas no ChM-I mRNA is detectable in the mouse mesenchymal precursor cell line C3H10T1/2, nor the osteoblastic cell line MC3T3-E1 [20, 55] . Following the induction of type II collagen (Col2a1) mRNA, the level of ChM-I transcripts in cells increases as differentiated cells became mature and declines as the cells became hypertrophic and calcified. In addition, parathyroid hormone, which blocks the progression of chondrogenesis, inhibits the expression of ChM-I mRNA in both ATDC5 cells and rabbit costal chondrocytes in culture [20, 56] . Growth stimulation by FGF-2 also markedly suppresses ChM-I expression in cultured chondrocytes. However, treatment with BMP-2 or activin, which facilitates chondrocyte differentiation and maturation, have only marginal effects on the levels of ChM-I mRNA. In contrast, TGF-clearly suppresses these levels [56] .
The initial characterization of the human ChM-I gene promoter has been previously reported [27] . Methylation has also been shown to participate in the control of the ChM-I promoter by regulating the binding of the transcriptional activator Sp3 [57] . However, the structure and regulation of the ChM-I promoter and enhancer, that ensures the tissue-specific transcription of the gene, are not yet fully understood. Sox9, a transcription factor and member of the Sox family, is a potent activator of the chondrocyte-specific enhancer of the Col2a1 gene and has an essential role in chondrogenesis [58, 59] . Osteo-chondroprogenitor cells are in fact derived from Sox9-expressing mesenchymal cells [60] . Sox5, Sox6 and Sox9 also cooperatively activate the expression of the Col2a1 chondrocyte differentiation marker in C3H10T1/2 cells [61] . Furthermore, as reported by Chung and coworkers [62] , adenoviral expression of the Sox9 protein in conjunction with Sox5 and Sox6 induces chondrocyte differentiation in mouse embryonic stem cells and in human mesenchymal stem cells. Moreover, following the induction of the established chondrocyte marker genes such as Col2a1, Col9a1, Col11a2, and aggrecan, ChM-I transcripts are also induced. Significantly, the combination of expression of Sox family members successfully induces the expression of ChM-I mRNA, even in adult dermal fibroblasts which are non-chondrogenic cells (Fig. (9) ). A timecourse analysis of this ChM-I induction was found to be distinct from that of Col2a1 or aggrecan, indicating the possibility that the transcriptional activation of the ChM-I gene is not directly activated by Sox9, but is brought about as a consequence of chondrocyte differentiation.
During endochondral ossification, cartilage switches its phenotype from anti-angiogenic to pro-angiogenic at the center of the cartilaginous bone templates. The level of ChM-I mRNA declines and the ChM-I protein stored in the ECM rapidly disappears as the cartilage cells undergo differentiation from the mature prehypertrophic stage to the hypertrophic/calcifying stage (Fig. (8) ) [20] . Matrix remodeling by MMP13 and VEGF expression initiates vascular invasion into calcified cartilage that recruits osteoclasts, chondroclasts and osteoprogenitor cells [9, 63, 64] . The Cbfa1/Runx2 transcription factor mediates this phenotypic transition of cartilage as well as osteoblastic differentiation. Targeted disruption of the Cbfa1/Runx2 gene results in the loss of bone formation in the mutant mice [65, 66] . A high level of ChM-I expression was found to be maintained throughout the cartilage rudiments in these mutant mice [67] . Moreover, expression of a Cbfa1/Runx2 transgene under the control of the Col2a1 promoter in these mutant mice rescued cartilage transition phenotype and restores the suppression of ChM-I expression and activation of VEGF expression in the center of the bone rudiments. Along with chondrocyte hypertrophy and vascular invasion, multinucleated chondroclastic cells that resorb the hypertrophic cartilage matrix were found in these rescued animals, despite the absence of osteoblasts [67] . Thus, Cbfa1/Runx2 participates in the repression of ChM-I gene expression that is dependent upon the differentiation of chondrocytes.
USE OF THE CHM-I DOMAIN AS A THERAPEUTIC TARGET AND ITS ACTIVITY IN VIVO
ChM-I null mice have been generated by targeted disruption [68, 69] . No overt abnormalities were detectable during the process of endochondral bone formation in embryogenesis or in cartilage development during the growth stages of the mice. However, a . (9) . Induction of the chondrocyte phenotype by forced expression of the Sox gene Trio (Sox 5, Sox 6 and Sox 9) in adult human dermal fibroblasts [62] . After cells in spheroid cultures were transduced with adenoviruses, the levels of ChM-I mRNA were monitored on the indicated day and compared to those for the Col2a1 and Aggrecan genes. significant increase in bone mineral density was unexpectedly found in adult ChM-I null mice due to reduced bone remodeling. Bone histomorphometry analysis further suggested that the trabecular bone volumes in these mutant animals were 2.5-fold higher than wild-type. An imbalance between osteoclastic bone resorption and osteoblastic bone formation accounted for the phenotype observed in the adult null mice, indicating that ChM-I plays a role as a bone-remodeling factor [69] . Interestingly, targeted disruption of the TSP-2 gene also resulted in increased bone mineral density [70] and recently the phenotypes of TeM null mice were reported [36] . Loss of TeM expression by gene targeting abated tenocyte proliferation and led to a reduced tenocyte density in tendons. Deposition of other ECM components, including type I, II, III, and VI collagens and decorin, lumican and aggrecan, was not affected, but the caliber of the collagen fibrils varied significantly and these exhibited increased maximal diameters at the newborn stage. These findings suggest an involvement of TeM in postnatal tendon maturation. However, the TeM null mice had normal vascular density in their tendons and no apparent vascular phenotype was detectable in null mice lacking both TeM and ChM-I [36] . An increase of large-diameter fibrils in tendons and irregular contacts between tenocytes and fibrils were also described in TSP-2 null mice.
As the list of known anti-angiogenic molecules in the body has increased, it has become more difficult to study the role of each individual factor in the anti-angiogenic barrier in vertebrates by targeted disruption of the gene. Multiple active molecules are likely to participate in the anti-angiogenic resistance of tissues to vascular invasion. Thus, in many cases, null mutant mice exhibit no apparent abnormalities in either vascular development or angiogenesis. The mild vascular phenotypes that have been reported in TSP-2 null mice and in endostatin/type XVIII collagen null mice are the exception rather than the rule [71, 72] . As shown in Fig. (8) , ChM-I protein is stored in the ECM of the avascular zone of cartilage, which completely overlaps the region of ChM-I gene expression. ChM-I protein is removed from the ECM prior to vascular invasion into the cartilaginous bone rudiments during skeletal development [20] . TSP-2 is also expressed in cartilage and perichondrium [73, 74] . Cartilage and fibrocartilage also contain endostatin/type XVIII collagen, even though the concentration of this factor has been estimated to be much lower than ChM-I [24, 75] . These observations may account, in part, for the lack of an apparent vascular phenotype in ChM-I and/or TeM null mice [36, 69] . These anti-angiogenic molecules are localized in a tight association with the ECM in the core domain of the avascular zone (and can even be tethered to the cell surface) of mesenchymal tissues and have little chance to come into direct contact with the vasculature during normal development. This implies that they are not involved in the developmental program that underlies patterning and morphogenesis. They are a determinant of tissue responses to the challenge of vascular invasion and, in this respect, it is interesting and important to study either adult or aged animals under pathological conditions.
As mentioned above, articular cartilage expresses ChM-I at a level lower than growth plate cartilage [54] . In rats, ChM-I immunoreactivity was strong in the inter-territorial space of the ECM and also in the cytoplasm in the intermediate and deep layers of the articular cartilage. As articular cartilage matures, this immunoreactivity was observed to be localized around the hypertrophic chondrocyctes in the deep layer and to gradually decline following the maturation of the tissue. Although it is detectable, ChM-I expression was found to be markedly weak in the superficial zone [53, 76] . These observations suggest that the articular surface of cartilage becomes vulnerable with age. In an osteoarthritis (OA) model prepared by surgical transection of the anterior cruciate ligament and removal of the menisci in adult rats, mature ChM-I protein has been suggested to escape from the interterritorial matrix of articular cartilage at an early stage after surgery [76] , whereas expression of the ChM-I gene is upregulated, probably to compensate for this rapid loss of protein. A decrease of ChM-I in the superficial zone occurs prior to the loss of proteoglycans and type II collagen, and is followed by the upregulation of VEGF-165 in the medial zone of cartilage (2.8-fold), compared with the lateral zone of OA cartilage or the control cartilage. In contrast, the expression of VEGF-121 is unchanged during this process. Furthermore, in the degenerative intervertebral discs of patients, ChM-I immunoreactivity was found to be elevated in the residual chondrocytes via a defense mechanism against the degenerative processes that occur in discs with age [77] .
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease in which massive synovial cell proliferation, leukocyte infiltration and abnormal angiogenesis all lead to the development of pannus. To test the therapeutic potential of ChM-I as a target in the treatment of angiogenic diseases, we examined the effects of recombinant human ChM-I (rhChM-I) during the induction of experimental arthritis [78] . First, BALB/c mice were primed with methylated bovine serum albumin (mBSA) and injected intraperitoneally with rhChM-I at the time of priming. Antigen-induced arthritis (AIA) was also induced in these mice by injection with methylated bovine serum albumin into the ankle joints at 2 weeks after priming. By subsequent evaluation of arthritis in this model system using maximum hind-paw thickness and histological examination, rhChM-I was observed to significantly suppress the development of AIA. Similarly, DBA/1 mice were injected intradermally with bovine type collagen to induce collagen-induced arthritis (CIA). As shown in Fig. (10) , intraperitoneal injection of rhChM-I significantly inhibited the development of CIA and only 50% of the mice that had received rhChM-I (10 g) for 3 consecutive days developed the disease. Moreover, histopathologic examinations of these mice revealed massive mononuclear cell infiltration and edema in the controls, whereas both of these features were suppressed in rhChM-I treated animals.
As previously reported in our laboratory [20] , thymus expresses a low level of ChM-I. In situ hybridization analyses have also revealed that ChM-I transcripts are clearly present in the cortex, but not in the medulla of thymus [78] , suggesting that ChM-I derived from thymic stromal cells may participate in T cell development and function. Misaki and co-workers also demonstrated in an earlier study that rhChM-I suppresses the proliferative response of both mouse splenic T cells and human peritoneal blood T cells that had been stimulated with anti-CD3/CD28 antibodies in a dosedependent manner [78] . Production of interleukin-2 was also found to be decreased by rhChM-I in mouse CD4 T cells. Moreover, rhChM-I also suppresses the proliferation of synovial cells prepared from the joints of RA patients [78] . In addition to its antiangiogenic effects, suppression of T cell responses and synovial cell proliferation further indicate the unique therapeutic potential of ChM-I as all of these features would be predicted to ameliorate the effects of RA.
Pleomorphic adenoma of the salivary glands is characterized by the mixed appearance of epithelial and mesenchymal-like elements, and the expression of ChM-I in this disease is associated with the formation of chondroid elements and inversely correlates with the presence of a CD34 endothelial marker [79, 80] . This suggests that ChM-I is involved in both hypovascularity and in chondroid differentiation in this type of tumor. Benign tumors such as enchondromas and exostoses express a level of ChM-I mRNA that is similar to normal articular cartilage (Fig. (11) ). In contrast, the level of ChM-I mRNA was found to be extremely low in chondrosarcomas [81] , even in grade I cases where the expression of other cartilage markers, such as type II collagen and aggrecan, is retained. A marked reduction in ChM-I expression may therefore participate in the susceptibility of chondrosarcoma to tumor angiogenesis. OUMS-27 human chondrosarcoma cells maintain the Fig. (11) . The relative levels of ChM-I mRNA in human chondrogenic tumors in comparison with articular cartilage [81] . The levels of ChM-I mRNA was estimated by competitive PCR using cDNA from grade I chondrosarcomas (CS), enchondromas (Ench), exostoses (Exo) and articular cartilage (AC). The values shown were plotted using a logarithmic scale of the means ± standard deviation. differentiated phenotype of chondrocytes, including active synthesis of ECM with aggrecan and type II collagen [82] . Moreover OUMS-27 cells express substantial levels of VEGF but are devoid of ChM-I [83] . These cells form cartilage-like nodules in monolayer cultures, and form grade II chondrosarcomas with associated tumor angiogenesis when implanted in nude mice. Taking advantage of this OUMS-27 xenograft tumor model, we tested the effect of rhChM-I treatment, as shown in Fig. (12) . The growth of OUMS-27 chondrosarcomas and the extent of tumor angiogenesis was successfully inhibited by the local administration of purified rhChM-I [81] . Similarly, the growth of HT-29 human colon adenocarcinoma cells was also inhibited. We then examined the effects of the C-terminal domain of human TeM on tumor growth and angiogenesis by adenoviral expression. BL-6 melanoma cells transduced with recombinant adenovirus were subcutaneously injected into C57BL/6 mice. The expression of the hTeM C-domain resulted in the successful inhibition of tumor growth in vivo [34] . Subsequent histological examination indicated that the C-terminal domain of TeM also suppressed tumor-induced angiogenesis as effectively as ChM-I. Recently, a tumor type that accompanies the overexpression of ChM-I was reported [84] . Multiple endocrine neoplasia type 2A (MEN 2A) and type 2B (MEN 2B) syndromes are caused by distinctive mutations in the RET receptor tyrosine kinase, and the gene expression profiles of medullary thyroid carcinomas (MTCs) from patients with these syndromes have previously been compared. Microarray analyses of these tumors revealed that many genes involved in the epithelial to mesenchymal transition are upregulated in MEN 2B MTCs. Among these, ChM-I was expressed at markedly high levels, specifically in MEN 2B, and was localized to malignant thyroid C cells [84] . The overexpression of ChM-I had no direct role in tumorigenesis, but the high levels of ChM-I in malignant thyroid C cells were found to be associated with skeletal abnormalities in MEN 2B patients, providing a possible molecular basis for the development of the well-known, but previously enigmatic features of the MEN2 syndromes.
CONCLUSIONS
A variety of anti-angiogenic peptides have been identified during the past decade in the circulatory system as cryptic inhibitors of angiogenesis that are derived from the macromolecular components of the basement membrane [11, 85] . Studies in vitro and in vivo have also demonstrated that TeM and the ChM-I precursor are members of a novel family of type II transmembrane proteins and are capable of releasing their C-terminal domains that contain a conserved Cys-rich region of 71 amino acids. Current data suggest that this Cys-rich region plays a central role in the antiangiogenic properties of these molecules, thus providing a unique opportunity to design a therapeutic target for tumor angiogenesis and other angiogenic disorders. Studies involving structure-activity correlation will be further required, however, to discern the minimal structural requirement for activity. Moreover, although it is not yet known how these molecules confer an anti-angiogenic signal to vascular endothelial cells, ChM-I and/or TeM null mice have shown phenotypes similar to those of mice lacking TSP-2, indicating that these endogenous angiogenesis inhibitors may act through a common signaling pathway [36, 69] . The TeM Cterminal domain, in addition to ChM-I, has also been shown to specifically inhibit endothelial adhesion to vitronectin. Interaction of TeM and ChM-I with integrins that are present on vascular endothelial cells is highly likely to be the important target for such analysis [34] .
We have experienced a dramatic increase in the available knowledge of the regulation of vascular development and angiogenesis during the past decade. VEGF is now recognized as a key element in the regulation of angiogenesis under both physiological and pathological conditions [41] and blocking VEGF signaling has emerged as a novel strategy for anti-angiogenic therapies in cancer. In this regard, optimal scheduling of antiangiogenic therapy with chemotherapy, and/or radiation therapy, is likely to be critical for the effective use of anti-angiogenic agents. Vessels of a therapeutic target will also need to be initially normalized to yield the best therapeutic outcome [86] . Detailed analysis of its expression pattern in vivo also indicates that ChM-I counterbalances VEGF expression in the avascular regions of the mesenchyme and that a shift in this balance underlies the phenotypic switching in tissues during normal development, and in the remodeling of mesenchymal tissues [9, 67, 69] . Hence, a more detailed understanding of the binding mechanisms of ChM-I in the ECM in the future will be crucial to maintain the angiogenic balance for normalization and to enable a later shift to an antiangiogenic state during therapy.
